Treatment with the Smallpox Antiviral Tecovirimat (ST-246) Alone or in Combination with ACAM2000 Vaccination Is Effective as a Postsymptomatic Therapy for Monkeypox Virus Infection |
| |
| Authors: | Aklile Berhanu Jonathan T. Prigge Peter M. Silvera Kady M. Honeychurch Dennis E. Hruby Douglas W. Grosenbach |
| |
| Affiliation: | aSIGA Technologies, Inc., Corvallis, Oregon, USA;bSouthern Research Institute, Frederick, Maryland, USA |
| |
| Abstract: | The therapeutic efficacies of smallpox vaccine ACAM2000 and antiviral tecovirimat given alone or in combination starting on day 3 postinfection were compared in a cynomolgus macaque model of lethal monkeypox virus infection. Postexposure administration of ACAM2000 alone did not provide any protection against severe monkeypox disease or mortality. In contrast, postexposure treatment with tecovirimat alone or in combination with ACAM2000 provided full protection. Additionally, tecovirimat treatment delayed until day 4, 5, or 6 postinfection was 83% (days 4 and 5) or 50% (day 6) effective. |
| |
| Keywords: | |
|
|
